Introduction
============

Fascin is a cytoskeletal protein, is one of the important members of the Fascin family of proteins and is located on chromosome 7q22([@b1-mco-0-0-2069]). An N-terminal serine participates in actin binding, which is also the phosphorylation site of protein kinase C. The phosphorylation of this site regulates the binding between Fascin and actin, and also increased the formation of pseudopodia on the surface of the cell membrane ([@b1-mco-0-0-2069]). Fascin is an actin-binding protein that can alter the cytoskeleton to form pseudopodia and microspores, increase the motility of epithelial cells, and reduce adhesion between cells and the extracellular matrix, thereby promoting cell migration ([@b2-mco-0-0-2069]), and also partakes in signal transduction ([@b3-mco-0-0-2069]). Fascin can catalyze the polymerization of actin and regulate the formation of microfilaments and filamentous pseudopodia on the cell surface, increasing the mobility of the epithelium and increasing cell surface projections, to increase cell migration, invasion and metastasis of tumor cells ([@b4-mco-0-0-2069]). Progression and invasion of colorectal cancer are closely associated with the increase in the motility of cancer cells, and the structural changes of the kinetic protein cytokine skeleton and the structure and function of the three-dimensional actuation microfilament are regulated and controlled by numerous kinetic protein binding proteins ([@b5-mco-0-0-2069]). Findings have shown that an increased expression of Fascin is closely associated with malignant biological behaviors, such as poor survival and metastasis in patients with colorectal cancer ([@b6-mco-0-0-2069]).

Fascin is involved in progression, survival and migration, and the expression of MMP-2 and collagen genes in human hepatic stellate cells, via a FAK-PI3K-AKT signaling pathway ([@b7-mco-0-0-2069]). PI3K may also regulate Skp2-mediated degradation of p27 through downstream signaling molecules (such as PKC, p70S6K and SGK, amongst others), and thus regulate the proliferation of liver cancer cells ([@b8-mco-0-0-2069]). Fascin is involved in STAT3 signaling in response to oncostatin M and interleukin-6 in human breast cancer cells, STAT3 directly increases the expression of Fascin, and this underlies the migration of breast cancer cells ([@b9-mco-0-0-2069]). The STAT3-SKP2 molecular network controls the development of cervical cancer ([@b10-mco-0-0-2069]). Fascin serves an important role in laryngeal cancer cell transition from G1 to the S phase ([@b11-mco-0-0-2069]).

Fascin expression is upregulated in lung cancer, thyroid, ovarian and liver cancer ([@b12-mco-0-0-2069]), and is associated with a poor prognosis, Tumor-Node-Metastasis (TNM) staging and lymph node and distant metastases ([@b16-mco-0-0-2069]). Simultaneously, the expression of Fascin-1 in the outer layer of the tumor is higher compared with the inner tumor, suggesting that it may be associated with tumor invasion ([@b17-mco-0-0-2069]). The upregulation of Fascin in cells can result in increased in cell membrane process formation, dissociation of the cell from the extracellular matrix, and thus an increase in cell motility, which serves a key role in invasion and lymph node metastasis ([@b18-mco-0-0-2069]). Hayashi *et al* ([@b21-mco-0-0-2069]) detected the expression of Fascin-1 in the early stages of liver formation using immunohistochemistry. In particular, in the embryonic stage, the expression of Fascin-1 is significantly increased in liver buds and hepatocytes. These results suggest that the expression of Fascin-1 may be associated with migratory activity of hepatocytes during the early hepatogenesis ([@b21-mco-0-0-2069]). In the present study, a meta-analysis and bioinformatics analysis was performed to provide evidence of the association between Fascin expression and clinicopathological factors in patients with colorectal cancer.

Materials and methods
=====================

### Literature search and selection criteria

Articles included in the present analysis were searched for in PubMed, Web of Science, Wanfang data, SinoMed and CNKI (June, 2019) using the following key words and modifiers: Fascin OR Fascin-1 OR FSCN1 AND colorectal OR colon OR rectum OR rectal AND cancer OR carcinoma OR tumor OR adenocarcinoma. Inclusion criteria for studies were: i) Studies using immunohistochemistry to detect the expression of Fascin or Fascin-1; ii) articles which included an association between Fascin expression and prognosis in colorectal cancer; and iii) articles assessing the association between Fascin expression and clinicopathological parameters, such as depth of invasion, lymph node metastasis and TNM stages, amongst others. The exclusion criteria were: i) Abstracts, case reports, reviews and meeting notes; ii) studies with a small sample size (n\<30); iii) repeat publications or repeat data; and iv) and animal-based studies.

### Data extraction and quality assessment

The information regarding all eligible publications was extracted by two reviewers, and the authors, year of publication, nationality of the patients, antibody companies, number of cases and controls, risks for cancer and follow-up outcomes are presented in [Table I](#tI-mco-0-0-2069){ref-type="table"}. Any disagreements regarding any of these data were resolved by discussion. The quality of the studies was independently assessed by two reviewers according to Newcastle Ottawa Oncomine Scale (NOS; [ohri.ca/programs/clinical_epidemiology/oxford.htm](ohri.ca/programs/clinical_epidemiology/oxford.htm)). The methods were assessed based on consistency of sample selection, comparability and ascertainment of outcomes.

### Bioinformatics analysis

*FSCN1* gene expression levels were analyzed using Oncomine ([oncomine.org](oncomine.org)), the largest chip-based oncogene database and integrated data mining platform. Multiple analysis (fold change) and the expression ratio of *FSCN1* in the range of 0.5-2.0, and there was no significant differential expression of the gene. Genes where the T statistic (T-test) exceeded a specific value was considered an abnormality. Whether the comparison was statistically significant was determined by calculating the confidence of the difference*.* The differences in *FSCN1* mRNA expression levels were compared between colorectal tissue (including the colon and the rectum), normal tissue, adenoma and colorectal cancer. All data were log-transformed, median centered per array, and the standard deviation was normalized to a single value for each array. The expression data were obtained (RNA-seqV2) and clinicopathological data of colorectal cancer from The Cancer Genome Atlas (TCGA) database ([cancer.gov](cancer.gov)) were analyzed using TCGA-assembler in R software. The raw data were integrated, *FSCN1* expression in colorectal cancer was analyzed and compared with the clinicopathological and prognostic data of patients with colorectal cancer.

### Statistical analysis

Revman version 5.3 (cochrane.es) was used for data analysis. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to estimate the expression of Fascin based on the clinicopathological parameters of patients with colorectal cancer. Initially, the heterogeneity of the original documents were assessed. Statistical significance of the pooled ORs were determined using Z tests. If there was no significance in the heterogeneity, a fixed effect model (Mantel-Haenszel method) was used, otherwise, a random effect model (Der Simonian and Laird method) was used. The effect of heterogeneity was quantified using an I^2^ test. Using the following cut-off values; 25, 50 and 75%, heterogeneity was subdivided into low, medium and high degrees, respectively. Publication bias was evaluated using funnel plot and quantified using Begg\'s test and Egger\'s test to assess funnel plot asymmetry. A funnel plot was used to evaluate publication bias. COX risk regression models were used for univariate and multivariate analysis. Meta-analyses were performed using Revman 5.3 and data obtained from TCGA was analyzed using SPSS version 17.0, and compared using a Student\'s t-test. Two-sided P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Study selection and characteristics

As shown in [Fig. 1](#f1-mco-0-0-2069){ref-type="fig"}, a total of 17 articles were found which assessed the relationship between Fascin expression and clinical pathology or prognosis of patients with colorectal cancer. Only 14 articles included analysis of normal colorectal tissue ([@b22-mco-0-0-2069]), and 6 included analysis of colorectal adenoma ([@b24-mco-0-0-2069],[@b27-mco-0-0-2069],[@b29-mco-0-0-2069],[@b32-mco-0-0-2069]). These 15 articles were used in the meta-analysis for comparison between Fascin expression and clinicopathological features of colorectal cancer. Additionally, there were 4 articles that discussed the prognostic significance of Fascin expression and its relationship clinicopathological or prognostic indicators of colorectal cancer ([@b23-mco-0-0-2069],[@b29-mco-0-0-2069],[@b30-mco-0-0-2069],[@b36-mco-0-0-2069]). All these studies evaluated the expression of Fascin and the risk of colorectal cancer using immunohistochemistry. The detailed characteristics of these articles are presented in [Table I](#tI-mco-0-0-2069){ref-type="table"}.

### Forest plot of OR for the association between Fascin expression and clinicopathological parameters of colorectal cancer

The relationship between Fascin expression and tumor susceptibility in colorectal normal mucosa tissues were assessed in 14 studies, with 1,484 cancer patients and 1,004 controls collectively. The expression of Fascin was upregulated in colorectal cancer compared with normal mucosa ([Fig. 2A](#f2-mco-0-0-2069){ref-type="fig"}; OR=7.78, 95% CI=6.14-9.87, P\<0.00001). Additionally, the cancer risk of Fascin-positive adenoma was also assessed, and the same trend were observed as in colorectal cancer using 329 cancer cases and 236 adenoma cases ([Fig. 2B](#f2-mco-0-0-2069){ref-type="fig"}; OR=0.23, 0.15-0.34, P\<0.00001). The meta-analysis showed that Fascin expression was associated with depth of invasion (OR=0.31, 95% CI=0.19-0.50, P\<0.00001), lymph node metastasis (OR=3.07, 95% CI=1.72-5.46, P=0.0001), Dukes stage (OR=0.14, 95% CI=0.04-0.46, P=0.0001), dedifferentiation (OR=0.42, 95% CI=0.19-0.94, P=0.04) and TNM stage (OR=0.38, 95% CI=0.21-0.71, P=0.003) ([Fig. 2C-H](#f2-mco-0-0-2069){ref-type="fig"}). However, Fascin was not associated with distant metastasis (OR=2.26, 95% CI=0.78-6.51, P=0.13). The survival data are presented in [Fig. 2I](#f2-mco-0-0-2069){ref-type="fig"}, and based on the 4 datasets, it was shown that Fascin expression was associated with a less favorable prognosis in patients with colorectal cancer (hazard ratio=0.48, 95% CI=0.38-0.60, P\<0.00001).

### Publication bias

Publication bias was qualitatively determined using funnel plots ([Fig. 3](#f3-mco-0-0-2069){ref-type="fig"}). An individual study was removed from the pooled analysis, and then sensitivity analysis was used to assess the impact of that individual study on the aggregated results. According to Egger\'s test, the present meta-analysis had no apparent publication bias.

### Relationship between Fascin expression and bioinformatics analysis in patients with colorectal cancer

According to Hong\'s datasets, *FSCN1* mRNA expression was upregulated in colon carcinoma tissues compared with the normal tissues ([Fig. 4A](#f4-mco-0-0-2069){ref-type="fig"}, P\<0.05). In Kaiser and TCGA dataset, *FSCN1* mRNA expression was also upregulated in colon mucinous adenocarcinoma tissues compared with colon tissues ([Fig. 4B](#f4-mco-0-0-2069){ref-type="fig"} and [C](#f4-mco-0-0-2069){ref-type="fig"}, P\<0.05). Notterman\'s and Ki\'s data showed increased *FSCN1* mRNA expression levels in colon adenocarcinoma tissues compared with the normal colon tissue ([Fig. 4D](#f4-mco-0-0-2069){ref-type="fig"} and [E](#f4-mco-0-0-2069){ref-type="fig"}, P\<0.05). According to Gaedcke\'s data, the expression of *FSCN1* mRNA in rectal adenocarcinoma was higher compared with normal tissue ([Fig. 4F](#f4-mco-0-0-2069){ref-type="fig"}, P\<0.05). Skrzypczak\'s data showed that the expression of *FSCN1* mRNA was higher in colon adenoma and colon carcinoma compared with normal tissue ([Fig. 4G-J](#f4-mco-0-0-2069){ref-type="fig"}, P\<0.05), and also showed that *FSCN1* mRNA expression was upregulated in colorectal carcinoma compared with colorectal tissue ([Fig. 4K](#f4-mco-0-0-2069){ref-type="fig"}, P\<0.05).

According to the data obtained from TCGA, univariate analysis showed a positive correlation between *FSCN1* mRNA expression and overall prognosis in patients with colorectal cancer ([Fig. 4L](#f4-mco-0-0-2069){ref-type="fig"}, P\<0.05). Multivariate analysis was performed using a Cox risk scale model, which showed that distant metastasis was an independent prognostic factor for colorectal cancer ([Table II](#tII-mco-0-0-2069){ref-type="table"}, P\<0.05). Fascin expression was positively correlated with depth of invasion and microsatellite instability (MSI) of colorectal cancer ([Fig. 4M](#f4-mco-0-0-2069){ref-type="fig"} and [N](#f4-mco-0-0-2069){ref-type="fig"}, P\<0.05). These data also showed that *FSCN1* mRNA expression levels were higher in the colon compared with the rectum ([Fig. 4O](#f4-mco-0-0-2069){ref-type="fig"}, P\<0.05), and that upregulated *FSCN1* mRNA expression levels were negatively correlated with serum carcinoembryonic antigen (CEA) levels in all patients with cancer ([Fig. 4P](#f4-mco-0-0-2069){ref-type="fig"}, P\<0.05).

Discussion
==========

The Fascin family of proteins consists of 3 members; Fascin-1-3 ([@b37-mco-0-0-2069]). Fascin-1 is widely expressed in smooth muscle tissues, vascular endothelium, fibroblasts and in neural crest cells ([@b40-mco-0-0-2069],[@b41-mco-0-0-2069]). Fascin-2 expression is confined to retinal photoreceptor cells, and Fascin-3 is only expressed in the testis ([@b38-mco-0-0-2069],[@b39-mco-0-0-2069]). Fascin has been studied in different types of tumors, such as breast cancer, colon cancer, brain cancer, esophageal cancer, stomach cancer, lung cancer, urinary bladder cancer and hematological malignancies ([@b42-mco-0-0-2069]). In normal epithelia of the bile duct, breast, colon, ovary, pancreas and stomach, the expression of Fascin is usually completely negative ([@b49-mco-0-0-2069]). Increased expression of Fascin is associated with a less favorable prognosis in patients with lung, gastric, esophageal or breast cancer ([@b45-mco-0-0-2069],[@b46-mco-0-0-2069],[@b50-mco-0-0-2069],[@b51-mco-0-0-2069]). To demonstrate the association between Fascin expression and its clinicopathological features, a meta-analysis of 17 articles was performed which were selected based on the NOS scores.

Fascin expression is upregulated in colorectal cancer, but is not expressed in normal colorectal tissues. The studies showed that the expression of Fascin was associated with an invasive phenotype and a poor prognosis in patients with colorectal cancer. Thus, it is hypothesized that Fascin protein is universally expressed in epithelial tumors ([@b35-mco-0-0-2069]). Fascin expression was negatively associated with distant metastases. In cell culture, in cells treated with recombinant Fascin, the migratory and invasive capacities of colorectal cancer cells are increased ([@b40-mco-0-0-2069]). Similar findings have been obtained in other types of epithelial cells, suggesting that Fascin may facilitate a more aggressive tumor phenotype ([@b18-mco-0-0-2069],[@b51-mco-0-0-2069]). In the present study, Fascin protein expression was found to be positively associated with depth of invasion, lymph node metastasis, Dukes stage, dedifferentiation and TNM stage.

The mechanism by which Fascin is upregulated during tumorigenesis, invasion and metastasis may be associated with multiple signaling pathways. Previous reports suggest that amplification or overexpression of c-erbB-2/HER-2 may affect the upregulation of Fascin expression ([@b52-mco-0-0-2069]). A study found that Wnt signaling may also have an effect on Fascin activity, suggesting that anomalies in the Wnt signaling pathway may result in upregulation of Fascin expression in tumor cells ([@b53-mco-0-0-2069]). Exogenous TGF-β and EGF induce the expression of Fascin, and this induction is dependent on the activation of ERK ([@b54-mco-0-0-2069],[@b55-mco-0-0-2069]), a downstream molecule of the Ras signaling pathway. Inhibition of phosphorylation of ERK results in a decrease in the expression levels of Fascin ([@b54-mco-0-0-2069]), suggesting that activation of the downstream molecules of the ERK-Ras pathway results in increased Fascin expression in tumor cells. Fu *et al* ([@b54-mco-0-0-2069]) found a significant upregulation of Fascin expression in experimental autoimmune neuritis sciatic nerves which was associated with disease severity. The interaction between Fascin and PKC may be regulated by cannabinoid signaling, which controlled neuroblast migration *in vivo*. It was also shown that Fascin upregulation marked a shift to the migratory neuroblast stage and was a key regulator of neuroblast activity ([@b55-mco-0-0-2069]). Fascin can stabilize actin bundles in the invasive pseudopod structure, which may promote the metastatic potential of tumor cells ([@b56-mco-0-0-2069],[@b57-mco-0-0-2069]). Additionally, Fascin promotes epithelial-mesenchymal transition through the formation of pseudopodium, and formation of a mesothelial cell layer ([@b58-mco-0-0-2069]). Previous studies showed that LMP1 mediated the upregulation of Fascin, and this was dependent on NF-κB, where both NF-κB and Fascin contributed to an invasion and migration in LMP1-expressing lymphocytes ([@b59-mco-0-0-2069]). Fascin expression is significantly associated with Tiam1 expression. Tiam1 activates Rac, and activated Rac affects the movement of cytoskeleton by inducing actin aggregation at the plasma membrane, resulting in formation of filopodia, and thus inducing invasion and metastasis of tumor cells ([@b26-mco-0-0-2069]).

Zhang *et al* ([@b60-mco-0-0-2069]) showed there was a positive correlation between Twist and Fascin mRNA expression levels in colorectal cancer, suggesting that they both served a synergistic role in the development and progression of colorectal cancer. In the present study, it was shown that there was a positive correlation between *FSCN1* mRNA expression levels and overall prognosis in patients with colorectal cancer, and distant metastasis was an independent prognostic factor for colorectal cancer. However, Fascin protein expression levels were not associated with distant metastasis, and this may be due to the sample size. Simultaneously, Fascin expression was positively correlated with depth of invasion. In the univariate analysis, there may be false or indirect associations between independent and dependent variables, which are adjusted for and thus may disappear in the multivariate analysis. The purpose of multivariate analysis is to determine the influencing factors with independent effects, and to estimate the effect size by controlling the influence of other confounding factors.

The present study has some limitations. First, potential publication bias stems from the fact that published results were predominantly positive. Second, the patients included in the studies were only from Asia and America. Different levels of medical development in different areas may influence the results. Third, extraction of survival data, such as incomplete extraction, may affect results. Fourth, small sample sizes may influence associations in some articles. Finally, the difference in the expression of Fascin between normal tissues and adenoma was not assessed.

In conclusion, Fascin expression is upregulated in colorectal cancer and adenoma. Fascin expression was positively associated with depth of invasion, lymph node metastasis, Dukes stage, TNM staging, dedifferentiation and a less favorable prognosis in patients with colorectal cancer. *FSCN1* mRNA expression was positively associated with depth of invasion, MSI, low serum CEA levels in colorectal cancer and with a less favorable prognosis in patients with colorectal cancer as an independent factor.
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###### 

Forest plot of the relationship between Fascin expression and clinicopathological parameters of patients with colorectal cancer. Plots of the association between (A) cancer and normal mucosa, (B) cancer and adenoma, (C) depth of invasion (T~is-2~ and T~3-4~), (D) lymph node metastasis \[LN and (LN- and Forest plot of the relationship between Fascin expression and clinicopathological parameters of patients with colorectal cancer. Plots of the association between (E) DM (DM-vs. DM+), (F) Dukes stage (A+B vs. C+D), (G) dedifferentiation (dedifferentiation- vs. dedifferentiation+), (H) TNM stage (I-II and III-IV) and (I) survival (Fascin+ vs. Fascin-). CI, confidence interval; TNM, Tumor-Node-Metastasis; DM, distant metastasis.

![](mco-13-02-0119-g01)

![](mco-13-02-0119-g02)

![Funnel plot for testing publication bias between Fascin expression and colorectal carcinogenesis. Publication bias was analyzed based on risk degrees of Fascin expression in (A) colorectal mucosa and (B) adenoma for colorectal carcinogenesis. Additionally, publication bias was also tested between Fascin expression and clinicopathological features of colorectal cancer, (C) including depth of invasion, (D) lymph node metastasis, (E) distant metastasis, (F) Dukes stage, (G) differentiation, (H) TNM stage and (I) survival. TNM, Tumor-Node-Metastasis.](mco-13-02-0119-g03){#f3-mco-0-0-2069}

###### 

*FSCN1* mRNA expression in colorectal carcinogenesis. (A) Expression of Fascin was significantly upregulated in colon carcinoma compared with the normal colon mucosa. (B) TCGA and (C) Kaiser databases showed that *FSCN1* was upregulated in colon mucinous adenocarcinoma compared with the normal colon mucosa. (D and E) *FSCN1* expression was higher in colon adenocarcinoma compared with normal colon mucosa and (F) adenocarcinoma. (G and H) Based on the Skrzypczak2 database, *FSCN1* upregulation in colon adenoma was higher compared with normal colon mucosa. (I and J) Expression of Fascin was significantly upregulated in colon carcinoma compared with the normal colon mucosa based on the Skrzypczak2 (K) Expression of Fascin was significantly upregulated in colon carcinoma compared with the normal colon mucosa based on the Skrzypczak database. (L) Univariate analysis showed a positive relationship between *FSCN1* mRNA expression and an overall improved prognosis in patients with colorectal cancer. (M and N) Fascin expression was positively correlated with depth of invasion and MSI in colorectal cancer. (O) *FSCN1* mRNA expression was higher in the colon cancer compared with rectal. (P) Increased *FSCN1* mRNA expression was negatively correlated with serum CEA levels in all patients with cancer. HR, hazard ratio; FSCN, Fascin; MSI, microsatellite instability; CEA, carcinoembryonic antigen; TCGA, The Cancer Genome Atlas.
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###### 

Primary characteristics of the eligible studies.

  Author, year   Country     Ethnicity   Antibody supplier                Cases   Control   Risk to cancer   Outcome    Quality   (Refs.)
  -------------- ----------- ----------- -------------------------------- ------- --------- ---------------- ---------- --------- -----------------------
  Zhao, 2014     China       China                                        126     126       Increased        \-         7         ([@b31-mco-0-0-2069])
  Yi, 2013       China       China       Sunbio                           60      60        Increased        \-         8         ([@b34-mco-0-0-2069])
  Xue, 2010      China       USA         Dako                             28      5         Increased        \-         8         ([@b28-mco-0-0-2069])
  Song, 2010     China       China       Mxb                              40      20        Increased        \-         8         ([@b32-mco-0-0-2069])
  Chan, 2010     Australia   USA         Dako                             446     433       Increased        Negative   9         ([@b29-mco-0-0-2069])
  Yao, 2014      China       China       Mxb                              40      20        Increased        Negative   8         ([@b30-mco-0-0-2069])
  Yang, 2006     China       USA         Dako                             41      20        Increased        \-         8         ([@b33-mco-0-0-2069])
  Seung, 2012    Korea       USA         Dako                             74      52        Increased        \-         8         ([@b35-mco-0-0-2069])
  Kong, 2016     China       USA         Clplor                           87      28        Increased        Negative   8         ([@b23-mco-0-0-2069])
  Li, 2015       China       China       Mxb                              86      40        Increased        \-         8         ([@b24-mco-0-0-2069])
  Liu, 2007      China       China       Mxb                              80      40        Increased        \-         8         ([@b25-mco-0-0-2069])
  Ding, 2008     China       China       Chemicon                         100     100       Increased        \-         8         ([@b26-mco-0-0-2069])
  Li, 2010       China       China       Mxb                              60      30        Increased        \-         8         ([@b27-mco-0-0-2069])
  Jung, 2011     Korea       USA         Thermo Fisher Scientific, Inc.   186     24        Increased        Negative   8         ([@b36-mco-0-0-2069])
  Pang, 2011     China       USA         Neomarker                        60      20        Increased        \-         8         ([@b22-mco-0-0-2069])

###### 

Multivariate analysis of hazardous factors in the prognosis of patients with colorectal cancer.

  Clinicopathological features   Hazard ratio (95% CI)   P-value
  ------------------------------ ----------------------- ---------
  T-stage, Tis~-2~/T~3-4~        1.265 (0.477-3.354)     0.636
  Lymph node status, -/+         0.774 (0.176-3.391)     0.734
  Distant metastasis, -/+        2.247 (1.212-4.165)     0.010
  TNM staging, I-II/III-IV       2.674 (0.541-13.212)    0.227
  *FSCN* mRNA expression         1.430 (0.877-2.330)     0.151

CI, confidence interval.
